Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

561. Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective

Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective 19660494 2009 09 28 2010 02 25 2009 09 28 1096-0260 49 2-3 2009 Aug-Sep Preventive medicine Prev Med Central obesity and cigarette smoking are key determinants of cardiovascular disease deaths in Australia: a public health perspective. 153-7 10.1016/j.ypmed.2009.07.019 Our objective is to develop a parsimonious model to predict coronary heart disease (CHD) and (...) cardiovascular disease (CVD) deaths using individual components of the Framingham risk score plus measures of central obesity. 15 year mortality follow-up of 8662 representative Australian adults in the National Heart Foundation Risk Factor Prevalence Survey of 1989, excluding those with a baseline history of heart disease, stroke or diabetes. Measures included blood pressure, fasting lipids, smoking history, body mass index (BMI), waist circumference (WC) and waist to hip ratio (WHR). Multivariable logistic

EvidenceUpdates2009

562. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the better not pout children! Study

Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the better not pout children! Study 19796740 2009 10 02 2009 10 29 2015 11 19 1558-3597 54 15 2009 Oct 06 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. 1467-75 10.1016/j.jacc.2009.06.020 The purpose of this study was to assess (...) the ability of plasma B-type natriuretic peptide (BNP) to diagnose significant cardiovascular disease (CVD) in the pediatric population. BNP has been shown to be reliable in detecting ventricular dysfunction and heart failure in adults. Timely and accurate identification of significant pediatric heart disease is important but challenging. A simple blood test could aid the front-line physician in this task. Subjects without a history of heart disease with findings possibly attributable to significant CVD

EvidenceUpdates2009

563. Cardiovascular diseases and risk of hip fracture.

Cardiovascular diseases and risk of hip fracture. CONTEXT: Recent studies indicate common etiologies for cardiovascular disease (CVD) and osteoporotic fractures. OBJECTIVES: To examine the relation between CVD and risk of hip fracture in twins and evaluate the relative importance of genetics and lifestyle factors in this association. DESIGN, SETTING, AND PARTICIPANTS: A cohort of all 31,936 Swedish twins born from 1914-1944 was followed up from the age of 50 years. The National Patient Registry (...) of ischemic heart disease compared with 1.2 per 1000 person-years for those without a CVD diagnosis. The multivariable-adjusted hazard ratio (HR) of hip fracture after a diagnosis of heart failure was 4.40 (95% confidence interval [CI], 3.43-5.63); after a stroke, the HR was 5.09 (95% CI, 4.18-6.20); after a diagnosis of peripheral atherosclerosis, the HR was 3.20 (95% CI, 2.28-4.50); and after an ischemic heart disease event, the HR was 2.32 (95% CI, 1.91-2.84). Identical twins without heart failure and

JAMA2009

564. A Prospective Study of Bone Lead Concentration and Death From All Causes, Cardiovascular Diseases, and Cancer in the Department of Veterans Affairs Normative Aging Study

A Prospective Study of Bone Lead Concentration and Death From All Causes, Cardiovascular Diseases, and Cancer in the Department of Veterans Affairs Normative Aging Study 19738141 2009 09 22 2009 10 08 2016 11 22 1524-4539 120 12 2009 Sep 22 Circulation Circulation A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. 1056-64 10.1161/CIRCULATIONAHA.108.827121 Blood lead (...) -, and race-adjusted hazard ratio for ischemic heart disease mortality (n=62 deaths) in the highest tertile was 8.37 (95% confidence interval, 1.29 to 54.4). Results were similar for tibia lead. Bone lead was not associated with cancer, and blood lead was not associated with any mortality category. We found bone lead to be associated with all-cause and cardiovascular mortality in an environmentally exposed population with low blood lead levels. This study suggests that cumulative lead exposure from prior

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

565. Perceived Level of Life Enjoyment and Risks of Cardiovascular Disease Incidence and Mortality. The Japan Public Health Center-Based Study

Perceived Level of Life Enjoyment and Risks of Cardiovascular Disease Incidence and Mortality. The Japan Public Health Center-Based Study 19720937 2009 09 15 2009 10 08 2015 11 19 1524-4539 120 11 2009 Sep 15 Circulation Circulation Perceived level of life enjoyment and risks of cardiovascular disease incidence and mortality: the Japan public health center-based study. 956-63 10.1161/CIRCULATIONAHA.108.834176 Perceived level of life enjoyment, a positive psychological condition that reflects (...) the ability to engage pleasurably with the environment, may relate to risks of cardiovascular disease. This prospective cohort study attempted to examine the effects of perceived level of life enjoyment on cardiovascular disease incidence and mortality among Japanese community residents. Subjects were 88 175 Japanese men and women 40 to 69 years of age who were free of cardiovascular disease at baseline and followed up for a median of 12.0 years and were included in the Japan Public Health Center-Based

EvidenceUpdates2009

566. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey

Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey 19608594 2009 08 17 2010 05 21 2016 11 25 1522-9645 30 16 2009 Aug European heart journal Eur. Heart J. Association between degenerative aortic valve disease and long-term exposure to cardiovascular risk factors: results of the longitudinal population-based KORA/MONICA survey. 2044-53 10.1093/eurheartj/ehp287 Degenerative (...) aortic valve disease (DAVD), a common finding in the elderly, is associated with an increased risk of death due to cardiovascular causes. Taking advantage of its longitudinal design, this study evaluates the prevalence of DAVD and its temporal associations with long-term exposure to cardiovascular risk factors in the general population. We studied 953 subjects (aged 25-74 years) from a random sample of German residents. Risk factors had been determined at a baseline investigation in 1994/95

EvidenceUpdates2009

567. Does IQ explain socio-economic differentials in total and cardiovascular disease mortality? Comparison with the explanatory power of traditional cardiovascular disease risk factors in the Vietnam Experience Study

Does IQ explain socio-economic differentials in total and cardiovascular disease mortality? Comparison with the explanatory power of traditional cardiovascular disease risk factors in the Vietnam Experience Study 19602715 2009 08 03 2009 11 05 2016 11 22 1522-9645 30 15 2009 Aug European heart journal Eur. Heart J. Does IQ explain socio-economic differentials in total and cardiovascular disease mortality? Comparison with the explanatory power of traditional cardiovascular disease risk factors (...) in the Vietnam Experience Study. 1903-9 10.1093/eurheartj/ehp254 The aim of this study was to examine the explanatory power of intelligence (IQ) compared with traditional cardiovascular disease (CVD) risk factors in the relationship of socio-economic disadvantage with total and CVD mortality, that is the extent to which IQ may account for the variance in this well-documented association. Cohort study of 4289 US male former military personnel with data on four widely used markers of socio-economic position

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

568. Cardiovascular disease - primary prevention.

Cardiovascular disease - primary prevention. Cardiovascular disease - primary prevention. | National Guideline Clearinghouse Search Sign In Username or Email * Password * Remember Me Don't have an account? Guideline Summary NGC:007148 This guideline summary has been withdrawn from NGC. Please update your bookmarks. View all withdrawn summaries in the . About NGC Guideline Summaries NGC's guidelines summaries contain information systematically derived from original guidelines. New on NGC

Medical Services Commission, British Columbia2009

569. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease

Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease 19660689 2009 08 07 2009 08 31 2015 11 19 1558-3597 54 7 2009 Aug 11 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk (...) for coronary heart disease. 601-8 10.1016/j.jacc.2009.05.022 We investigated whether a multiple biomarkers strategy that includes plasma levels of endothelium-derived microparticles (EMP), reflecting endothelial dysfunction, can improve prediction of future cardiovascular events in patients at high risk for coronary heart disease (CHD). Detailed risk stratification using multiple biomarkers can provide clinical benefits in high-risk patients. Endothelial dysfunction has been described as a predictor

EvidenceUpdates2009

570. Impact of androgen deprivation therapy on cardiovascular disease and diabetes

Impact of androgen deprivation therapy on cardiovascular disease and diabetes 19506162 2009 07 17 2009 09 16 2017 02 24 1527-7755 27 21 2009 Jul 20 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. 3452-8 10.1200/JCO.2008.20.0923 PURPOSE Use of androgen deprivation therapy (ADT) may be associated with an increased risk of diabetes mellitus but the risk (...) of both acute myocardial infarction (AMI) and cardiovascular mortality remain controversial because few outcomes and conflicting findings have been reported. We sought to clarify whether ADT is associated with these outcomes in a large, representative cohort. METHODS Using linked administrative databases in Ontario, Canada, men age 66 years or older with prostate cancer given continuous ADT for at least 6 months or who underwent bilateral orchiectomy (n = 19,079) were matched with men with prostate

EvidenceUpdates2009

571. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases

Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases 19660608 2009 08 07 2009 08 27 2015 11 19 1879-1913 104 4 2009 Aug 15 The American journal of cardiology Am. J. Cardiol. Utility of C-reactive protein for cardiovascular risk stratification across three age groups in subjects without existing cardiovascular diseases. 538-42 10.1016/j.amjcard.2009.04.020 The relative utility of conventional and novel (...) risk factors in predicting cardiovascular disease (CVD) in relation to age remains unclear. We examined the discriminative ability of C-reactive protein (CRP) and Framingham risk score across young (35 to 50 years), middle (51 to 65 years), and older (> or =65 years) aged participants from the Scottish Health Surveys (n = 5,944, 44.5% men). CRP data and conventional risk factors were collected at baseline. During an average follow-up of 7.1 years, 308 CVD events (a composite of fatal and nonfatal

EvidenceUpdates2009

572. Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial

Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial 19491386 2009 07 21 2009 08 03 2016 12 15 1938-3207 90 2 2009 Aug The American journal of clinical nutrition Am. J. Clin. Nutr. Effects of vitamins C and E and beta-carotene on the risk of type 2 diabetes in women at high risk of cardiovascular disease: a randomized controlled trial. 429-37 10.3945/ajcn.2009.27491 Vitamin C, vitamin E (...) of cardiovascular disease (CVD) or > or =3 CVD risk factors were randomly assigned to receive vitamin C (ascorbic acid, 500 mg every day), vitamin E (RRR-alpha-tocopherol acetate, 600 IU every other day), beta-carotene (50 mg every other day), or their respective placebos. During a median follow-up of 9.2 y, a total of 895 incident cases occurred among 6574 women who were free of diabetes at baseline. There was a trend toward a modest reduction in diabetes risk in women assigned to receive vitamin C compared

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

573. The Strong Women-Healthy Hearts program: reducing cardiovascular disease risk factors in rural sedentary, overweight, and obese midlife and older women

The Strong Women-Healthy Hearts program: reducing cardiovascular disease risk factors in rural sedentary, overweight, and obese midlife and older women 19443826 2009 06 16 2009 07 22 2017 02 20 1541-0048 99 7 2009 Jul American journal of public health Am J Public Health The StrongWomen-Healthy Hearts program: reducing cardiovascular disease risk factors in rural sedentary, overweight, and obese midlife and older women. 1271-7 10.2105/AJPH.2008.145581 We tested a community-based intervention (...) designed to reduce cardiovascular disease risk in sedentary midlife and older women who were overweight or obese. In a randomized controlled trial conducted in 8 counties in Arkansas and Kansas, counties were assigned to the intervention (a 12-week twice-weekly heart health program) group or to the delayed-intervention control group. Ten to fifteen women were selected from each site, and participants' weight, waist circumference, diet, physical activity, and self-efficacy were measured before and after

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

574. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease

Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease 19576324 2009 07 06 2009 07 24 2015 11 19 1879-1913 104 1 2009 Jul 01 The American journal of cardiology Am. J. Cardiol. Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. 74-81 (...) 10.1016/j.amjcard.2009.02.047 Niacin has beneficial effects on a patient's lipid and lipoprotein profiles and cardiovascular risk, particularly at doses >2 g/day, but is underused due to flushing. Laropiprant (LRPT), a selective prostaglandin D(2) receptor-1 antagonist, decreases flushing associated with extended-release niacin (ERN). We compared flushing with ERN/LRPT dosed by a simplified 1-g --> 2-g regimen versus gradually titrated niacin extended-release (N-ER; given as NIASPAN, trademark of Kos

EvidenceUpdates2009

575. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial)

Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from the COURAGE Trial) 19576311 2009 07 06 2009 07 24 2015 11 19 1879-1913 104 1 2009 Jul 01 The American journal of cardiology Am. J. Cardiol. Impact of optimal medical therapy with or without percutaneous coronary intervention on long-term cardiovascular end points in patients with stable coronary artery disease (from (...) , addition of PCI did not decrease the incidence of major cardiovascular outcomes including cardiac death or the composite of cardiac death/MI/ACS/stroke in patients with stable coronary artery disease. Boden William E WE VA Western New York Health Care System, Buffalo General Hospital, and the University at Buffalo, Buffalo, NY, USA. wboden@kaleidahealth.org O'Rourke Robert A RA Teo Koon K KK Maron David J DJ Hartigan Pamela M PM Sedlis Steven P SP Dada Marcin M Labedi Mohammed M Spertus John A JA

EvidenceUpdates2009

576. Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study)

Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study) 19576355 2009 07 06 2009 07 21 2016 10 19 1879-1913 104 2 2009 Jul 15 The American journal of cardiology Am. J. Cardiol. Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). 247-53 10.1016/j.amjcard.2009.03.026 Several biomarkers have been documented, singly or jointly (...) , to improve risk prediction, but the extent to which they improve prediction-model performance in populations with high prevalences of obesity and diabetes has not been specifically examined. The aim of this study was to evaluate the ability of various biomarkers to improve prediction-model performance for death and major cardiovascular disease (CVD) events in a high-risk population. The relations of 6 biomarkers with outcomes were examined in 823 American Indians free of prevalent CVD or renal

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

577. Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases?

Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? 19196734 2009 05 15 2009 06 17 2014 07 30 1468-201X 95 11 2009 Jun Heart (British Cardiac Society) Heart Does cigarette smoking exacerbate the effect of total cholesterol and high-density lipoprotein cholesterol on the risk of cardiovascular diseases? 909-16 10.1136/hrt.2008.147066 To explore whether an interaction between smoking and serum total (...) cholesterol (TC) and/or decreased levels of serum high-density lipoprotein cholesterol (HDLC) exists for any major subtype of cardiovascular disease. An individual participant overview of 34 cohort studies. The Asia-Pacific region. People aged >or=20 years without a particular condition or risk factor. Hazard ratios (HRs) and 95% confidence intervals (CIs) for both TC and HDLC by smoking status were estimated using Cox proportional hazard models adjusted for age and systolic blood pressure and stratified

EvidenceUpdates2009

578. Cardiovascular Diseases: Patient Brochures and Clinician Fact Sheets

Cardiovascular Diseases: Patient Brochures and Clinician Fact Sheets USPSTF Recommendations on Cardiovascular Disease Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser. Search | | | | | | | You Are Here: > > > Cardiovascular Diseases: Patient Brochures and Clinician Fact Sheets Cardiovascular Diseases Patient Brochures and Clinician Fact Sheets Partnership for Health: The Veterans Administration (VA), the Agency (...) for Healthcare Research and Quality (AHRQ), and the U.S. Preventive Services Task Force (USPSTF) . The Veterans Administration partnered with AHRQ to create patient brochures and fact sheets for health care providers that explain the USPSTF recommendations for several cardiovascular diseases. Patient Brochures Talk With Your Health Care Provider About... Health Care Provider Fact Sheets Current as of June 2009 Internet Citation: Cardiovascular Diseases: Patient Brochures and Clinician Fact Sheets . June 2009

Publication 3262009

579. Predicting the 30-year risk of cardiovascular disease: the framingham heart study

Predicting the 30-year risk of cardiovascular disease: the framingham heart study 19506114 2009 06 23 2009 07 14 2016 12 03 1524-4539 119 24 2009 Jun 23 Circulation Circulation Predicting the 30-year risk of cardiovascular disease: the framingham heart study. 3078-84 10.1161/CIRCULATIONAHA.108.816694 Present cardiovascular disease (CVD) risk prediction algorithms were developed for a < or =10-year follow up period. Clustering of risk factors at younger ages and increasing life expectancy (...) Metab Cardiovasc Dis. 2005 Dec;15(6):426-40 16314229 Heart. 2007 Feb;93(2):172-6 17090561 Adult Algorithms Cardiovascular Diseases blood epidemiology etiology physiopathology Female Follow-Up Studies Humans Incidence Life Expectancy Male Massachusetts Middle Aged Models, Theoretical Predictive Value of Tests Risk Factors Sex Factors Time Factors NIHMS128838 PMC2748236 2009 6 10 9 0 2009 6 10 9 0 2009 7 15 9 0 ppublish 19506114 CIRCULATIONAHA.108.816694 10.1161/CIRCULATIONAHA.108.816694 PMC2748236

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

580. Role of frailty in patients with cardiovascular disease

Role of frailty in patients with cardiovascular disease 19463525 2009 05 25 2009 06 18 2009 05 25 1879-1913 103 11 2009 Jun 01 The American journal of cardiology Am. J. Cardiol. Role of frailty in patients with cardiovascular disease. 1616-21 10.1016/j.amjcard.2009.01.375 Frailty is a geriatric syndrome of increased vulnerability to stressors that has been implicated as a causative and prognostic factor in patients with cardiovascular disease (CVD). The American Heart Association (...) . Davis Jewish General Hospital, McGill University, Montreal, Quebec, Canada. jonathan@afilalo.com Karunananthan Sathya S Eisenberg Mark J MJ Alexander Karen P KP Bergman Howard H eng Journal Article Review 2009 04 08 United States Am J Cardiol 0207277 0002-9149 AIM IM Activities of Daily Living Aged Body Composition Cardiovascular Diseases epidemiology mortality physiopathology Frail Elderly Geriatric Assessment Humans 56 2008 11 10 2009 01 31 2009 01 31 2009 5 26 9 0 2009 5 26 9 0 2009 6 19 9 0

EvidenceUpdates2009